Regen | search
Click here to view Regen news from 60+ newspapers.
Bookmark or Share- FDA Authorizes Shelf-Life Extension for REGEN-COV - HHS.govOn June 27, 2022, FDA authorized an extension to the shelf-life from 24 months to 30 months for specific lots of the refrigerated Regeneron monoclonal antibodies, casirivimab and imdevimab, administered together or REGEN-COV (see Table 1, Table 2, and Table 3 below).
- FDA Expands Authorized Use of REGEN-COV™ (casirivimab and imdevimab ...Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) updated the Emergency Use Authorization (EUA) for the investigational COVID-19 antibody cocktail REGEN-COV™ (casirivimab and imdevimab).
- FDA authorizes REGEN-COV mAb for prevention for COVID-19REGEN-COV also remains authorized for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of...
- FDA Authorizes REGEN-COV to Treat COVID-19 - Verywell HealthREGEN-COV is a type of monoclonal antibody treatment that helps reduce the risk of developing severe COVID-19 after someone has been exposed to the virus. It binds to the spike protein in SARS-CoV-2, the virus that causes COVID-19, and keeps it from attacking your cells.
- Regeneron Pharmaceuticals Inc. - MarketWatchREGN U.S.: Nasdaq. Regeneron Pharmaceuticals Inc. Watch list. NEW. Set a price target alert. Open. Last Updated: May 14, 2024 1:44 p.m. EDT Real time quote. $ 979.46. 2.50 0.26% Previous Close....
More
